These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10785289)

  • 1. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals.
    Shafer RW; Warford A; Winters MA; Gonzales MJ
    J Virol Methods; 2000 May; 86(2):143-53. PubMed ID: 10785289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.
    Shafer RW; Hertogs K; Zolopa AR; Warford A; Bloor S; Betts BJ; Merigan TC; Harrigan R; Larder BA
    J Clin Microbiol; 2001 Apr; 39(4):1522-9. PubMed ID: 11283081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
    J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients.
    Paolucci S; Baldanti F; Campanini G; Zavattoni M; Cattaneo E; Dossena L; Gerna G
    J Med Virol; 2001 Oct; 65(2):207-17. PubMed ID: 11536225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 7. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences.
    Yahi N; Tamalet C; Tourrès C; Tivoli N; Ariasi F; Volot F; Gastaut JA; Gallais H; Moreau J; Fantini J
    J Clin Microbiol; 1999 Dec; 37(12):4099-106. PubMed ID: 10565938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay.
    Wilson JW; Bean P; Robins T; Graziano F; Persing DH
    J Clin Microbiol; 2000 Aug; 38(8):3022-8. PubMed ID: 10921971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
    Cabana M; Clotet B; Martínez MA
    J Med Virol; 1999 Dec; 59(4):480-90. PubMed ID: 10534730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
    Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
    Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
    Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
    Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
    Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
    J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.
    Palmer S; Kearney M; Maldarelli F; Halvas EK; Bixby CJ; Bazmi H; Rock D; Falloon J; Davey RT; Dewar RL; Metcalf JA; Hammer S; Mellors JW; Coffin JM
    J Clin Microbiol; 2005 Jan; 43(1):406-13. PubMed ID: 15635002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.
    Hanna GJ; Johnson VA; Kuritzkes DR; Richman DD; Martinez-Picado J; Sutton L; Hazelwood JD; D'Aquila RT
    J Clin Microbiol; 2000 Jul; 38(7):2715-21. PubMed ID: 10878069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia.
    Ross L; Johnson M; DeMasi R; Liao Q; Graham N; Shaefer M; St Clair M
    AIDS; 2000 May; 14(7):813-9. PubMed ID: 10839589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
    Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
    AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sources and magnitude of intralaboratory variability in a sequence-based genotypic assay for human immunodeficiency virus type 1 drug resistance.
    Galli RA; Sattha B; Wynhoven B; O'Shaughnessy MV; Harrigan PR
    J Clin Microbiol; 2003 Jul; 41(7):2900-7. PubMed ID: 12843019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy.
    Kantor R; Zijenah LS; Shafer RW; Mutetwa S; Johnston E; Lloyd R; von Lieven A; Israelski D; Katzenstein DA
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1407-13. PubMed ID: 12512512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.